HilleVax

Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has entered into a licensing agreement with HilleVax Inc. (NASDAQ: HLVX), granting the US firm exclusive rights to develop, manufacture, and commercialize Kanghua’s recombinant hexavalent norovirus vaccine on a worldwide basis, excluding the Greater China region…